Document Classification

Section Type: RESULTS

Text: Patients receiving docetaxel were more likely to have grade 3 or 4 neutropenia (40. 2 % v 5. 3 % ; P <. 001), febrile neutropenia (12. 7 % v 1. 9 % ; P <. 001), neutropenia with infections (3. 3 % v 0. 0 % ; P =. 004), hospitalizations for neutropenic fever (13. 4 % v 1. 5 % ; P <. 001), hospitalizations due to other drug related adverse events (10. 5 % v 6. 4 % ; P =. 092), use of granulocyte colony-stimulating factor support (19. 2 % v 2. 6 %, P <. 001) and all grade alopecia (37. 7 % v 6. 4 % ; P <. 001) compared with patients receiving pemetrexed.